GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diaceutics PLC (OTCPK:DIUXF) » Definitions » Current Ratio

Diaceutics (Diaceutics) Current Ratio : 6.40 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Diaceutics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Diaceutics's current ratio for the quarter that ended in Dec. 2023 was 6.40.

Diaceutics has a current ratio of 6.40. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Diaceutics's Current Ratio or its related term are showing as below:

DIUXF' s Current Ratio Range Over the Past 10 Years
Min: 1.64   Med: 7.32   Max: 11.53
Current: 6.4

During the past 8 years, Diaceutics's highest Current Ratio was 11.53. The lowest was 1.64. And the median was 7.32.

DIUXF's Current Ratio is ranked better than
88.36% of 232 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.03 vs DIUXF: 6.40

Diaceutics Current Ratio Historical Data

The historical data trend for Diaceutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diaceutics Current Ratio Chart

Diaceutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 8.23 11.53 11.41 8.23 6.40

Diaceutics Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.41 10.17 8.23 7.99 6.40

Competitive Comparison of Diaceutics's Current Ratio

For the Diagnostics & Research subindustry, Diaceutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diaceutics's Current Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diaceutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Diaceutics's Current Ratio falls into.



Diaceutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Diaceutics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=35.494/5.548
=6.40

Diaceutics's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=35.494/5.548
=6.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diaceutics  (OTCPK:DIUXF) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Diaceutics Current Ratio Related Terms

Thank you for viewing the detailed overview of Diaceutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Diaceutics (Diaceutics) Business Description

Traded in Other Exchanges
Address
Kings Hall Health and Wellbeing Park, Dataworks, First Floor, Building Two, Antrim, Belfast, GBR, BT9 6GW
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives.